Clinical Trial Update: Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating botulinum toxin type A for Thromboangiitis Obliterans (Buerger's disease) and Raynaud phenomenon; the study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Thromboangiitis Obliterans

Drugs mentioned

• Botulinum toxin type A (botulinum toxin type A)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Buerger Disease, Raynaud Syndrome | Phase 3 | Status: NOT_YET_RECRUITING